Angiotensin IV and analogs as regulators of fibrinolysis
AssigneeBrighan & Women's Hospital
InventorDouglas E. Vaughan
Life of this patent
Estimating the term…
Abstract
Angiotensin IV (VAL-TYR-ILE-HIS-PRO-PHE), a degradation product of angiotensin II previously thought to be inactive, interacts directly with endothelial cells to induce expression of PAI-1 and thereby to inhibit clot lysis attributable to endogenous t-PA. Moreover, angiotensin IV does not effect substantial physiological changes (vasoconstriction, increased blood pressure, etc.) characteristic of angiotensin II. Fibrinolysis is promoted by reducing the amount or the effect of angiotensin IV. Fibrinolysis is inhibited by providing enhanced angiotensin IV. Methods of screening candidates for antagonizing angiotensin IV are also disclosed.
Claims9
An in vitro method of evaluating whether a compound will promote fibrinolysis, comprising:
- (a) providing cells having a receptor which specifically binds angiotensin IV and which are capable of expressing plasminogen activator inhibitor-1 (PAI-1) in the presence of angiotensin IV;
- and
- (b) contacting the cells with a mixture comprising angiotensin IV or an agonist of angiotensin IV and the compound to specifically bind said receptor;
- and
- (c) detecting the expression of PAI-1 to determine whether the compound induces substantial expression of PAI-1;
- and
- (d) selecting the compound as promoting fibrinolysis if it does not induce substantial expression of PAI-1.
An in vitro method of evaluating whether a compound will promote fibrinolysis, comprising:
- (a) providing cells having a receptor which specifically binds angiotensin IV and which are capable of expressing plasminogen activator inhibitor-1 (PAI-1) in the presence of angiotensin IV;
- and
- (b) contacting the cells with a mixture comprising angiotensin IV or an agonist of angiotensin IV and the compound to specifically bind said receptor;
- and
- (c) detecting the binding of angiotensin IV to said receptor to determine whether the compound reduces the amount of angiotensin IV binding to the receptor, relative to a control without the compound;
- and
- (d) detecting the expression of PAI-1 to determine whether the compound induces substantial expression of PAI-1;
- and
- (e) selecting the compound as promoting fibrinolysis if it reduces specific binding of angiotensin IV to the receptor and does not induce substantial expression of PAI-1.
Dependencies are inferred from the claim text.